menu search

CARA / Cara Therapeutics Faces Uncertainty Despite Potential Reimbursement Extension For Korsuva

Cara Therapeutics Faces Uncertainty Despite Potential Reimbursement Extension For Korsuva
Cara Therapeutics' Korsuva injection, approved for treating pruritus in adults with chronic kidney disease, may have its reimbursement period extended to 2027 by the US Medicare and Medicaid Services, potentially boosting the company's stock value. Despite a net loss of $26.7 million in Q1 2023, Cara Therapeutics has launched Kapruvia in several European countries and is progressing with Phase 3 trials for other potential treatments, indicating an active R&D pipeline. The company's financial outlook remains risky with ongoing losses and uncertainties in drug development, leading to a 70% stock devaluation since February. Cara remains a "Sell". Read More
Posted: Jul 14 2023, 17:11
Author Name: Seeking Alpha
Views: 091927

CARA News  

Cara Therapeutics (CARA) Reports Q2 Loss, Tops Revenue Estimates

By Zacks Investment Research
August 7, 2023

Cara Therapeutics (CARA) Reports Q2 Loss, Tops Revenue Estimates

Cara Therapeutics (CARA) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of a loss of $0.56. This compares to lo more_horizontal

Cara Therapeutics to Announce Second Quarter 2023 Financial Results on August 7, 2023

By GlobeNewsWire
July 24, 2023

Cara Therapeutics to Announce Second Quarter 2023 Financial Results on August 7, 2023

STAMFORD, Conn., July 24, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new more_horizontal

Cara Therapeutics Faces Uncertainty Despite Potential Reimbursement Extension For Korsuva

By Seeking Alpha
July 14, 2023

Cara Therapeutics Faces Uncertainty Despite Potential Reimbursement Extension For Korsuva

Cara Therapeutics' Korsuva injection, approved for treating pruritus in adults with chronic kidney disease, may have its reimbursement period extended more_horizontal

3 Small-Cap Stocks to Sell in June Before They Crash and Burn

By InvestorPlace
June 13, 2023

3 Small-Cap Stocks to Sell in June Before They Crash and Burn

Small-cap stocks, defined by a market capitalization between $300 million and $2 billion, can tempt investors looking for quick returns. However, thes more_horizontal

Cara Therapeutics, Inc. (CARA) Q1 2023 Earnings Call Transcript

By Seeking Alpha
May 15, 2023

Cara Therapeutics, Inc. (CARA) Q1 2023 Earnings Call Transcript

Cara Therapeutics, Inc. (NASDAQ:CARA ) Q1 2023 Earnings Conference Call May 15, 2023 4:30 PM ET Company Participants Matt Murphy - Manager, IR Christo more_horizontal

Cara Therapeutics (CARA) Reports Q1 Loss, Tops Revenue Estimates

By Zacks Investment Research
May 15, 2023

Cara Therapeutics (CARA) Reports Q1 Loss, Tops Revenue Estimates

Cara Therapeutics (CARA) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to lo more_horizontal

Cara Therapeutics, Inc. (CARA) to Announce First Quarter 2023 Financial Results on May 15, 2023

By MarijuanaStocks
May 1, 2023

Cara Therapeutics, Inc. (CARA) to Announce First Quarter 2023 Financial Results on May 15, 2023

Cara Therapeutics to Announce First Quarter 2023 Financial Results on May 15, more_horizontal

Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month - Cara Therapeutics (NASDAQ:CARA), AdaptHealth (NASDAQ:AHCO)

By Benzinga
March 14, 2023

Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month - Cara Therapeutics (NASDAQ:CARA), AdaptHealth (NASDAQ:AHCO)

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. more_horizontal


Search within

Pages Search Results: